BC Extra | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

Merck, Codexis design efficient synthesis of Phase II HIV therapy  Merck & Co. Inc. (NYSE:MRK) and Codexis Inc. (NASDAQ:CDXS) researchers designed a way to synthesize HIV therapy islatravir (MK-8591) via a three-step biocatalytic cascade in...
BC Extra | Jun 21, 2019
Financial News

June 20 Financial Quick Takes: Zymeworks raises $175M; plus Casdin, Scholar Rock and more

Zymeworks trades up after follow-on  Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) added $1.74 (10%) to $20.05 Thursday after raising $175 million late Wednesday through the sale of 9.7 million shares at $18 in a follow-on. The price...
BC Extra | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
BC Extra | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
BC Week In Review | Dec 1, 2017
Company News

Codexis, Nestle deal

In October, the Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) obtained an option from Codexis Inc. (NASDAQ:CDXS) to license exclusive worldwide rights to CDX-6114, an oral enzyme, to treat phenylketonuria. Codexis received $14 million...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Apr 7, 2017
Financial News

Codexis completes follow-on

Protein engineering company Codexis Inc. (NASDAQ:CDXS) raised $22 million on April 7 through the sale of 5.5 million shares at $4 in a follow-on underwritten by Jefferies and Craig-Hallum Capital. Codexis Inc. (NASDAQ:CDXS), Redwood City,...
BC Week In Review | Sep 28, 2015
Company News

Codexis deal

Codexis will use its CodeEvolver platform to develop an enzyme for use in an undisclosed company’s preclinical therapeutic development program. Codexis said a proof-of-concept study is expected to be completed in about six months. If...
BC Week In Review | Sep 7, 2015
Company News

Codexis Inc, Merck deal

Codexis granted Merck a non-exclusive, worldwide license to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing Merck therapeutics. Codexis will receive $5 million up front and an additional $13 million in...
BC Week In Review | Jul 28, 2014
Company News

GlaxoSmithKline, Codexis deal

Codexis granted GlaxoSmithKline a non-exclusive, worldwide license to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing existing GSK drugs. Under the license, GSK can also use the technology to develop new...
Items per page:
1 - 10 of 99
BC Extra | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

Merck, Codexis design efficient synthesis of Phase II HIV therapy  Merck & Co. Inc. (NYSE:MRK) and Codexis Inc. (NASDAQ:CDXS) researchers designed a way to synthesize HIV therapy islatravir (MK-8591) via a three-step biocatalytic cascade in...
BC Extra | Jun 21, 2019
Financial News

June 20 Financial Quick Takes: Zymeworks raises $175M; plus Casdin, Scholar Rock and more

Zymeworks trades up after follow-on  Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) added $1.74 (10%) to $20.05 Thursday after raising $175 million late Wednesday through the sale of 9.7 million shares at $18 in a follow-on. The price...
BC Extra | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
BC Extra | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
BC Week In Review | Dec 1, 2017
Company News

Codexis, Nestle deal

In October, the Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) obtained an option from Codexis Inc. (NASDAQ:CDXS) to license exclusive worldwide rights to CDX-6114, an oral enzyme, to treat phenylketonuria. Codexis received $14 million...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Apr 7, 2017
Financial News

Codexis completes follow-on

Protein engineering company Codexis Inc. (NASDAQ:CDXS) raised $22 million on April 7 through the sale of 5.5 million shares at $4 in a follow-on underwritten by Jefferies and Craig-Hallum Capital. Codexis Inc. (NASDAQ:CDXS), Redwood City,...
BC Week In Review | Sep 28, 2015
Company News

Codexis deal

Codexis will use its CodeEvolver platform to develop an enzyme for use in an undisclosed company’s preclinical therapeutic development program. Codexis said a proof-of-concept study is expected to be completed in about six months. If...
BC Week In Review | Sep 7, 2015
Company News

Codexis Inc, Merck deal

Codexis granted Merck a non-exclusive, worldwide license to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing Merck therapeutics. Codexis will receive $5 million up front and an additional $13 million in...
BC Week In Review | Jul 28, 2014
Company News

GlaxoSmithKline, Codexis deal

Codexis granted GlaxoSmithKline a non-exclusive, worldwide license to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing existing GSK drugs. Under the license, GSK can also use the technology to develop new...
Items per page:
1 - 10 of 99